Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
5/20/25 | Roche (RO) | Columvi for Diffuse Large B-Cell Lymphoma (DLBCL) - NHL | Subscribers Only | Subscribers Only | Subscribers Only |
5/20/25 | Johnson & Johnson (JNJ) | Darzalex Faspro for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
5/19/25 | Akcea Therapeutics | Tryngolza for Dyslipidemia / Hypercholesterolemia | Subscribers Only | Subscribers Only | Subscribers Only |
5/15/25 | Merck & Co (MRK) | Keytruda for Ovarian Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
5/14/25 | Arcellx (ACLX) | Anito-cel for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
04/24/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/13/2025 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
05/13/2025 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
05/17/2025 | Subscribers Only | Subscribers Only | Trial Data - Other |